Therapeutic Asset Ratings

3,272 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Head And Neck Cancer	National Cancer Institute (NCI)	P1/2	CC (44)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Sarcoma	National Cancer Institute (NCI)	P1/2	CC (44)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Vaginal Cancer	National Cancer Institute (NCI)	P1/2	CC (44)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap Vulva Cancer	National Cancer Institute (NCI)	P1/2	CC (44)
AXUMIN Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Capivasertib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Defactinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
FAPI74 Ovarian Cancer	National Cancer Institute (NCI)	P2	CC (43)
Fludeoxyglucose Ovarian Cancer	National Cancer Institute (NCI)	P2	CC (43)
Ipatasertib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Kras Tcr-Transduced Pbl Pancreatic Neoplasm	National Cancer Institute (NCI)	P2	CC (43)
Larotrectinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Luspatercept Acute Myeloid Leukemia	National Cancer Institute (NCI)	P2	CC (43)
Nogapendekin Alfa Inbakicept Neoplasm	National Cancer Institute (NCI)	P2	CC (43)
Osimertinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
pds01adc Prostate Cancer	National Cancer Institute (NCI)	P2	CC (43)
Sleeping Beauty Transposed Pbl Breast Cancer	National Cancer Institute (NCI)	P2	CC (43)
Sleeping Beauty Transposed Pbl Non-Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P2	CC (43)
Sleeping Beauty Transposed Pbl Ovarian Cancer	National Cancer Institute (NCI)	P2	CC (43)
Taselisib Melanoma	National Cancer Institute (NCI)	P2	CC (43)
Tcr Transduced T-Cells Breast Cancer	National Cancer Institute (NCI)	P2	CC (43)
Tcr Transduced T-Cells Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Tcr Transduced T-Cells Non-Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P2	CC (43)
Tcr Transduced T-Cells Ovarian Cancer	National Cancer Institute (NCI)	P2	CC (43)
Triadeno Vaccine Prostate Cancer	National Cancer Institute (NCI)	P2	CC (43)

Showing 2651 to 2675 of 3,272 assets

PreviousPage 107 of 131Next